Advances in the critical care management for patients with hematological malignancies.

IF 6.9 2区 医学 Q1 HEMATOLOGY
Elie Azoulay, Lara Zafrani, Joseph Nates, Alexis Maillard, Dara Chean, Bruno Ferreyro, Judith E Nelson, Philippe R Bauer, Kathryn Puxty, Cristina Gutierrez, Naike Bigé, Eric Mariotte, Sandrine Valade, Boris Boell, Kathleen Puntillo, Antoine Lafarge, Marcio Soares, Peter Schellongowski, Emmanuel Canet, Pedro Castro, Alexandre Demoule, Frédéric Pène, Laveena Munshi, Alexander Shimabukuro-Vornhagen, Thomas Staudinger, Lene Russell, Sara Fernandez, Matthias Kochanek, Virginie Lemiale, Michael von Bergwelt-Baildon, Michael Darmon, Ignacio Martin-Loeches
{"title":"Advances in the critical care management for patients with hematological malignancies.","authors":"Elie Azoulay, Lara Zafrani, Joseph Nates, Alexis Maillard, Dara Chean, Bruno Ferreyro, Judith E Nelson, Philippe R Bauer, Kathryn Puxty, Cristina Gutierrez, Naike Bigé, Eric Mariotte, Sandrine Valade, Boris Boell, Kathleen Puntillo, Antoine Lafarge, Marcio Soares, Peter Schellongowski, Emmanuel Canet, Pedro Castro, Alexandre Demoule, Frédéric Pène, Laveena Munshi, Alexander Shimabukuro-Vornhagen, Thomas Staudinger, Lene Russell, Sara Fernandez, Matthias Kochanek, Virginie Lemiale, Michael von Bergwelt-Baildon, Michael Darmon, Ignacio Martin-Loeches","doi":"10.1016/j.blre.2025.101306","DOIUrl":null,"url":null,"abstract":"<p><p>Hematological malignancies (HMs) are increasingly associated with life-threatening complications requiring intensive care unit (ICU) management. Recent advancements in therapies, diagnostics, and critical care protocols have improved outcomes for these patients, yet significant challenges persist. This manuscript explores the evolving landscape of critical care in hematology, emphasizing the unique complications, management strategies, and future directions in the field. Patients with HMs are particularly vulnerable to infections, sepsis, organ dysfunction, and treatment-related toxicities such as cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), and coagulopathies. Innovations in the management of acute respiratory failure, septic shock, and invasive fungal infections have contributed to better survival rates, yet outcomes remain suboptimal for certain high-risk groups. Furthermore, new therapies, including CAR-T cells, bispecific antibodies, and immune checkpoint inhibitors, present both opportunities and challenges in the ICU setting due to their potential toxicities. Emerging trends emphasize the importance of early ICU admission, multidisciplinary collaboration, and precision medicine in improving patient care. The integration of biomarker-driven strategies, advanced diagnostics, and artificial intelligence holds promise for optimizing therapeutic interventions and enhancing antimicrobial stewardship. Additionally, patient-centered approaches, including time-limited trials and goal-oriented discussions, aim to balance aggressive care with quality-of-life considerations. This review underscores the need for continued research to address disparities in access to care, improve long-term outcomes, and develop standardized protocols for managing critically ill hematology patients. By advancing the integration of oncology and critical care, clinicians can better navigate the complexities of modern therapies and provide holistic, evidence-based care that aligns with patient values and priorities.</p>","PeriodicalId":56139,"journal":{"name":"Blood Reviews","volume":" ","pages":"101306"},"PeriodicalIF":6.9000,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Blood Reviews","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.blre.2025.101306","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Hematological malignancies (HMs) are increasingly associated with life-threatening complications requiring intensive care unit (ICU) management. Recent advancements in therapies, diagnostics, and critical care protocols have improved outcomes for these patients, yet significant challenges persist. This manuscript explores the evolving landscape of critical care in hematology, emphasizing the unique complications, management strategies, and future directions in the field. Patients with HMs are particularly vulnerable to infections, sepsis, organ dysfunction, and treatment-related toxicities such as cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), and coagulopathies. Innovations in the management of acute respiratory failure, septic shock, and invasive fungal infections have contributed to better survival rates, yet outcomes remain suboptimal for certain high-risk groups. Furthermore, new therapies, including CAR-T cells, bispecific antibodies, and immune checkpoint inhibitors, present both opportunities and challenges in the ICU setting due to their potential toxicities. Emerging trends emphasize the importance of early ICU admission, multidisciplinary collaboration, and precision medicine in improving patient care. The integration of biomarker-driven strategies, advanced diagnostics, and artificial intelligence holds promise for optimizing therapeutic interventions and enhancing antimicrobial stewardship. Additionally, patient-centered approaches, including time-limited trials and goal-oriented discussions, aim to balance aggressive care with quality-of-life considerations. This review underscores the need for continued research to address disparities in access to care, improve long-term outcomes, and develop standardized protocols for managing critically ill hematology patients. By advancing the integration of oncology and critical care, clinicians can better navigate the complexities of modern therapies and provide holistic, evidence-based care that aligns with patient values and priorities.

恶性血液病患者重症监护管理进展。
恶性血液病(HMs)越来越多地与危及生命的并发症相关,需要重症监护病房(ICU)管理。治疗、诊断和重症监护方案的最新进展改善了这些患者的预后,但仍存在重大挑战。这份手稿探讨了血液学重症监护的不断发展的景观,强调独特的并发症,管理策略,并在该领域的未来方向。HMs患者特别容易发生感染、败血症、器官功能障碍和治疗相关毒性,如细胞因子释放综合征(CRS)、免疫效应细胞相关神经毒性综合征(ICANS)和凝血功能障碍。在急性呼吸衰竭、感染性休克和侵袭性真菌感染的治疗方面的创新有助于提高生存率,但某些高危人群的预后仍不理想。此外,包括CAR-T细胞、双特异性抗体和免疫检查点抑制剂在内的新疗法,由于其潜在的毒性,在ICU环境中既带来了机遇,也带来了挑战。新兴趋势强调早期ICU入院、多学科合作和精准医学在改善患者护理方面的重要性。生物标志物驱动策略、先进诊断和人工智能的整合有望优化治疗干预措施和加强抗菌药物管理。此外,以患者为中心的方法,包括有时间限制的试验和目标导向的讨论,旨在平衡积极的护理与生活质量的考虑。这篇综述强调需要继续研究,以解决在获得护理方面的差异,改善长期结果,并制定管理血液病危重患者的标准化方案。通过推进肿瘤学和重症监护的整合,临床医生可以更好地驾驭现代治疗的复杂性,并提供符合患者价值观和优先事项的整体循证护理。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Blood Reviews
Blood Reviews 医学-血液学
CiteScore
13.80
自引率
1.40%
发文量
78
期刊介绍: Blood Reviews, a highly regarded international journal, serves as a vital information hub, offering comprehensive evaluations of clinical practices and research insights from esteemed experts. Specially commissioned, peer-reviewed articles authored by leading researchers and practitioners ensure extensive global coverage across all sub-specialties of hematology.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信